Unusual presentation of ROS1 rearranged metastatic non-small cell lung cancer.

The spectrum of clinical and radiographic presentations of lung adenocarcinoma is increasingly broad, including in the metastatic setting. Here, we report on a patient who initially presented with a mild chronic cough that remained stable over a decade, with serial CT scans showing gradual worsening of multifocal areas of consolidation and ground-glass opacities of the bilateral lungs. The patient was ultimately diagnosed with ROS1 rearranged lung adenocarcinoma and achieved a dramatic response with entrectinib. This case highlights the variable presentation of non-small cell lung cancer (NSCLC) and the importance of comprehensive molecular testing for newly diagnosed metastatic NSCLC.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Catherine Shu reports a relationship with Arcus Biosciences Inc that includes: consulting or advisory. Catherine Shu reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory. Catherine Shu reports a relationship with Genentech that includes: consulting or advisory. Catherine Shu reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory. Catherine Shu reports a relationship with Beth Israel Deaconess Medical Center that includes: consulting or advisory. Catherine Shu reports a relationship with Takeda that includes: consulting or advisory. Catherine Shu reports a relationship with Gilead that includes: consulting or advisory If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Anjali Saqi reports a consulting/advisory relationship with the following: Veracyte, Boehringer Ingelheim, Genentech, Roche, Bristol Myers Squibb, Abbvie, Fieldworks, Medscape, Dedham, Qessential, Noreen Ellis, PeerView, Gilead.
(© 2024 The Authors.)